Phio Pharmaceuticals Corp (PHIO)

[The Other Guy]

You and me both on the MirImmune acquisition. The strategy was to acquire then partner. Problem is, any potential partner will see the issue with cash and will be able to leverage heavily against RXi. Our best hope is that what MirImmune had truly does work effectively and a partner puts some big dollars behind it. Keep in mind how relatively small the market cap is compared to the potential.

Pavco retiring doesn't bother me. Dispersyn is high caliber with a lot to prove. Pavco will still be onboard as an advisor. It also tells me the company is not losing focus on RX-109, RX-230 and the others. Dispersyn may move those along more quickly. Nothing against Pavco but I've worked with folks who are on the verge of retiring. Some coast in while others throw in the towel way too late.

It's time RXi start bringing home the bacon for it's shareholders.

I still don't know what to make of the high short interest. Either they smell blood in the water or there is a major hedge play in the works. Shorts rarely lose.